- Company name
- Cencora
- Sector
- Pharmaceutical distribution and specialty services
- About
- Cencora is one of the largest distributors of medicines in the United States. It buys medicines from manufacturers and delivers them to pharmacies, hospitals, health systems and physician practices. It also owns management services organizations for physician groups in oncology (OneOncology, bought in February 2026) and retina care (Retina Consultants of America), and it gives logistics and other services to drug makers. From October 1, 2026, it reports two segments: Pharmaceutical Distribution and Services, with revenue of $284.5 billion and operating income of $2.7 billion in fiscal 2026, and Specialty Pharmaceutical and Provider Services, with revenue of $45.4 billion and operating income of $1.7 billion. Total revenue was $337.4 billion in fiscal 2026. Its fiscal year ends on September 30. The shares trade on the New York Stock Exchange. The head office is in Conshohocken, Pennsylvania. Robert P. Mauch is President and Chief Executive Officer.
- Thesis
- Cencora trades close to its intrinsic value because investors pay a full price for its steady growth in drug distribution and specialty services, but they weigh the opioid settlements, the debt from its purchases of physician groups and the loss of some Walgreens volume. In fiscal 2026, adjusted diluted EPS rose 12.3% to $17.97, and Cencora expects $19.40 to $19.75 for fiscal 2027. For the value to rise, three things must be true. Operating income of the specialty segment, which includes the oncology and retina groups, must grow by 18% to 21% in fiscal 2027, as guided. The sale of Profarma and the merger of MWI Animal Health with Covetrus must close as planned; the guidance assumes March 31, 2027 for MWI. Changes to drug prices in the United States must not cut the fees that Cencora earns from manufacturers. The Q1 fiscal 2027 report, expected in early February 2027, is the next test. Lower margins or new opioid claims can keep the value flat.
- Risks
- A few customers give a large part of revenue, mainly Walgreens and a large mail order customer. A lost or changed contract can cut revenue and profit.
Cencora had an accrued litigation liability of $3,670 million at September 30, 2026, mainly for opioid settlements. Other opioid lawsuits continue, and their cost can be higher.
Changes to drug prices in the United States, such as lower list prices for brand medicines, can reduce the fees and margins of distributors.
GLP-1 medicines for diabetes and weight loss add revenue but have lower gross margins, so a larger share of them lowers the margin percentage.
The purchases of physician groups, such as OneOncology and American Oncology Network, add debt and can fail to give the planned profit.
- Balance sheet
- Cash: $4.9B
Debt: $11.3B
Net debt: $6.4B
Debt due within 12 months: $203M
Cencora funds itself mainly with payables to suppliers, bonds, term loans and cash flow. At September 30, 2026, cash and cash equivalents were $4,880 million, short-term debt $203 million and long-term debt $11,063 million. Long-term debt rose from $7,543 million a year earlier, because Cencora issued $3.0 billion of senior notes and $1.5 billion of term loans to pay for part of OneOncology. The accrued litigation liability was $3,670 million, and stockholders' equity was $3,681 million. In fiscal 2026, operating cash flow was $4,790 million, capital expenditures $910 million, share repurchases $1,000 million and dividends $477 million. Cencora expects adjusted free cash flow of about $3.5 billion in fiscal 2027. The quarterly dividend is $0.66 per share from November 2026. The purchase of American Oncology Network will need about $1.7 billion of cash when it closes, and the sales of MWI Animal Health and Profarma will bring cash in fiscal 2027.
As of 2026-09-30.
- Checkpoints
- Nov 4, 2026: Fiscal 2026 results and fiscal 2027 guidance. Passed. Watch: Adjusted diluted EPS at the high end of the guidance and EPS growth of 8% or more guided for fiscal 2027 pass; less fails. Outcome: Adjusted diluted EPS rose 12.3% to $17.97, and Cencora guided to $19.40 to $19.75 for fiscal 2027.
Feb 3, 2027 (estimate): Q1 fiscal 2027 results. Pending. Watch: A confirmed or higher fiscal 2027 EPS guidance and growth in specialty operating income pass; a guidance cut fails.
Mar 31, 2027 (estimate): Closing of the MWI Animal Health merger with Covetrus. Pending. Watch: Closing by March 31, 2027 with the planned cash proceeds passes; a delay or a lower price fails.
- Recent events
- 2026-11-04: Cencora reported fiscal 2026 results. Revenue rose 5.0% to $337.4 billion, GAAP diluted EPS was $17.95 and adjusted diluted EPS rose 12.3% to $17.97. For fiscal 2027, Cencora expects adjusted diluted EPS of $19.40 to $19.75 and adjusted free cash flow of about $3.5 billion. It introduced two new segments and raised the quarterly dividend by 10% to $0.66 per share.
2026-10-21: Cencora agreed to buy American Oncology Network, a network of more than 350 oncology providers in 21 states, at an enterprise value of $2.4 billion. Cencora expects to pay about $1.7 billion for a 75% interest if other holders keep 25%, and it expects the deal to add to adjusted diluted EPS in the second year after closing.
2026-08-12: Cencora said that some Walgreens volume outside the prime vendor agreement began to move to another supplier on July 1, 2026. The prime vendor agreement, which is most of the Walgreens business, did not change, and Cencora kept its fiscal 2026 guidance.
2026-02-18: Cencora agreed to merge MWI Animal Health with Covetrus. The deal values MWI at an enterprise value of $3.5 billion. Cencora will receive $1.25 billion in cash and $800 million of preferred equity, and keep 34.3% of the common equity of the combined company.
2026-02-13: Cencora issued $3.0 billion of senior notes, due from 2029 to 2056, to repay a term loan that paid for part of the purchase of OneOncology. The purchase closed on February 2, 2026.